

September 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Egypt, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 15 years.



Local expertise, global strength



3
Manufacturing plants



1,000+
Employees



1
R&D centre in Giza - 6th of October

Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

Manufacturing high-quality medicines

Our three strategically located plants produce a variety medicines in key therapeutic areas:

- Cephalosporin plant**
Delivers high-quality anti-infectives
- General formulation plant**
Manufactures a wide range of medicines in various dosage forms
- Oncology/ Immunosuppressant plant**
Dedicated to producing essential cancer treatments with the first immunosuppressant production capabilities in Egypt

Supporting patients on their health journey

We go beyond the production of medicine by developing disease awareness programmes for various therapeutic areas to support patients in managing their health.

A diversified portfolio of medicines

We offer the Egyptian patient over 158 medicines covering 12 therapeutic areas addressing a wide range of healthcare needs:



Oncology



Diabetes



Gastrointestinal



Cardiovascular



Anti-infectives



Others

Hikma in Egypt is **ranked #9** among the pharmaceutical companies based on sales¹

Hikma’s oral oncology plant with a dedicated immunosuppressant production area is **the first in Egypt**

Launching **2-3 new oral oncology** products annually

Hikma has a **2.6% market share** of the total Egyptian pharmaceutical market¹

Hikma has a **42% market share** in the overall Egyptian multiple sclerosis market²

References:
1. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source : IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period :MAT Aug. 2024, Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, TIG, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
2. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period :MAT Aug. 2024, Market definitions: Oral Multiple Sclerosis Medications Market (ATC3 N7A) reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
3. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period :MAT Aug. 2024, Market definitions: Oral Systemic and Oral Anti-infectives market - ATC3 J1A, J1b, J1C, J1D, J1E, J1F, J1G, J1H, J1J, J1K, J2A, J4A, J4B, J5B, J5C, J5D, J7E & J7X and NF123 AAA, AAG, AAK, ABA, ABC, ACA, ACY, BAA, BBC, BCA, DEP, DGB, DGI, DGK, DGM & DGN reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.